Dickmeyer Boyce Financial Management Inc. Acquires Shares of 10,505 Novo Nordisk A/S $NVO

Dickmeyer Boyce Financial Management Inc. bought a new position in Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,505 shares of the company’s stock, valued at approximately $386,000.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Gibbs Wealth Management raised its position in shares of Novo Nordisk A/S by 115.7% in the 1st quarter. Gibbs Wealth Management now owns 39,273 shares of the company’s stock worth $1,443,000 after purchasing an additional 21,065 shares during the last quarter. Sei Investments Co. grew its position in Novo Nordisk A/S by 53.7% during the 1st quarter. Sei Investments Co. now owns 486,550 shares of the company’s stock valued at $17,882,000 after purchasing an additional 169,906 shares during the last quarter. Cetera Investment Advisers increased its stake in Novo Nordisk A/S by 38.6% during the 1st quarter. Cetera Investment Advisers now owns 396,557 shares of the company’s stock valued at $14,573,000 after purchasing an additional 110,386 shares in the last quarter. AR Asset Management Inc. bought a new stake in Novo Nordisk A/S during the 1st quarter valued at about $583,000. Finally, Signature Equity Partners LLC raised its holdings in Novo Nordisk A/S by 491.0% in the first quarter. Signature Equity Partners LLC now owns 1,572 shares of the company’s stock worth $58,000 after buying an additional 1,306 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent analyst reports. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Wolfe Research started coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. Five analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Trading Down 0.0%

Shares of NYSE:NVO opened at $48.18 on Friday. The stock’s 50-day simple moving average is $46.28 and its two-hundred day simple moving average is $45.72. The stock has a market capitalization of $215.12 billion, a price-to-earnings ratio of 11.31, a PEG ratio of 4.39 and a beta of 0.77. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Analysts expect that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.